Associazione Nazionale Medici Cardiologi Ospedalieri



Tafamidis for treatment of Transthyretin cardiac amyloidosis: a real world experience

Vagnarelli Fabio Ancona(Ancona) – Centro cardiologico GM Lancisi – Azienda Ospedaliero-Universitaria delle Marche | Brugiatelli Leonardo Ancona(Ancona) – Centro cardiologico GM Lancisi – Azienda Ospedaliero-Universitaria delle Marche | Lofiego Carla Ancona(Ancona) – Centro cardiologico GM Lancisi – Azienda Ospedaliero-Universitaria delle Marche

Background: a regional network for cardiac amyloidosis (CA) was created in 2019 with the aim of enhancing disease awareness among physicians and favoring appropriate access to innovative diagnostic tools/therapies. The network includes all 14 Cardiology Departments and outpatient clinics from 5 Local Health Units.

Therapies for variant (ATTR-v) and wild-type (ATTR-wt) CA have recently become available in Italy. Selected centres with expertise in cardiomyopathies were identified to prescribe new modifying disease drugs. Tafamidis is the first medication approved for the treatment of ATTR-C. The landmark ATTRACT trial showed a reduction in cardiovascular mortality and cardiovascular-related hospitalization in patients treated with tafamidis compared to placebo. From October 2021 tafamidis can be prescribed in Italy according to AIFA criteria (only NYHA I/II patients eligible).

The aim of our study is to present the experience of our Network in prescribing tafamidis and to compare the clinical baselibe characteristics of our population and the ATTRACT trial population.

Methods: thanks to our network , 189 patients with ATTR-CA were referred to our Center.

58 ATTR patients were treated with tafamidis according to AIFA criteria, while 5 patients with variant-TTR and neuropathy received patisiran iv.

The causes of exclusion from tafamidis therapy are shown in figure 1.

We prospectively collected all the patientst treated with tafamidis from January 2022 until November 2023. All the data about clinical characteristics, laboratoy findings ECG, echo, bone scintigraphy and concomitant treatment were collected during routin follow-up visits anc compared to those of ATTRACT trial population.

Results: The main findings of our study are summarized in Table (fig,2)

The age of our population was similar to that of the patients enrolled in the ATTR-ACT trial (75,94 ± 11.4 vs. 74,5±7.2, P = 0.21).

Of note, our population does not include patients in NYHA class III as the AIFA prescriptive criteria exclude these patients from treatment in Italy. this implies a substantial difference in the distribution of the NYHA class compared to the attract population (p = 0.001). The outcome of our patient was excellent, the drug was well tolerated.

Conclusions: Implementing specific clinical network provided excellent results, allowing a precise phenotype/genotype characterization and favoring appropriate access to specific disease-modifying drugs.